Impact of IL-35 and presepsin on immunological, hematological, and biochemical parameters in COVID-19 patients

Document Type : Original Research

Authors
1 Department of biology, Sanandaj branch, Islamic azad university, Sanandaj, Iran
2 Department of Microbiology, College of Medicine, University of Babylon, Hilla, Iraq.
Abstract
Backgrounds: Immune-inflammatory responses appear to play a key role in severe SARS-CoV-2 infections. Interleukin-35 (IL-35) and presepsin (PSN) are inhibitory cytokine and pro-inflammatory interleukin, which play a crucial role in the immune system modulation, respectively. Therefore, the study of IL-35 and PSN interaction with other parameters may be critical for managing patients with COVID-19.

Materials & Methods: A total of 125 severe/critical COVID-19 patients and 60 healthy persons as a control group were enrolled in this work. These patients were admitted to Marjan medical city and Al-Sadeq hospital in Iraq during February to August 2022 and diagnosed as severe cases depending on the SpO2 percentage according to the guidelines released by the National Health World. Anti- and pro-inflammatory cytokines (IL-35 and PSN) were detected by ELISA technique.

Findings: Presepsin showed a positive correlation with admission to the respiratory care unit (RCU) (r= .022, p= .011). A negative correlation was found between presepsin and C- reactive protein (CRP) (r= .21, p= .018). Both PSN and IL-35 in biochemical tests showed a positive strong effect on glucose levels in COVID-19 patients (r= .234, p= .008 and r= .241, p= .007, respectively). IL-35 had a positive impact on alkaline phosphatase (ALP) (r= .28, p= .002). Hemoglobin (Hb) level showed a positive correlation with presepsin (r= .2, p= .02).

Conclusion: This study confirms the growing evidence showing the direct role of regulatory pro-inflammatory cytokines in the development and control of COVID-19 through the interaction with other parameters.

Keywords

Subjects


1- AL-Khikani FH, Ayit AS. A scoping review of SARS-CoV-2 and male infertility: Concerns and future prospects. Asian Pacific Journal of Reproduction. 2022;11:53.
2- Fauci AS, Lane HC, Redfield RR. Covid‐19 ‐ Navigating the Uncharted. N Engl J Med. 2020;382:1268‐1269.
3- AL-Khikani FH. COVID-19: Containment strategies and management options. Journal of Nature and Science of Medicine. 2020;3:221.
4- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med. 2020;382:1199‐1207.
5- Voto C, Berkner P, Brenner C. Overview of the pathogenesis and treatment of SARS-CoV-2 for clinicians: a comprehensive literature review. Cureus. 2020 ;12:76
6- Liu MX, Liu QY, Liu Y, Cheng ZM, Liu L, Zhang L, Sun DH. Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients. Connective tissue research. 2019;60:367-75.
7- Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. Journal of Interferon & Cytokine Research. 2018 ;38:423-39.
8- Chen X, Hao S, Zhao Z, Liu J, Shao Q, Wang F, Sun D, He Y, Gao W, Mao H. Interleukin 35: Inhibitory regulator in monocyte-derived dendritic cell maturation and activation. Cytokine. 2018;108:43-52.
9- Zhang J, Zhang Y, Wang Q, Li C, Deng H, Si C, Xiong H. Interleukin‐35 in immune‐related diseases: protection or destruction. Immunology. 2019;157:13-20.
10- Memar M, Baghi H. Presepsin: A promising biomarker for the detection of bacterial infections. Biomedicine & Pharmacotherapy 2019;111:649–56.
11- Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. International Journal of Infectious Diseases 2020;96:467–74.
12- Al-Khikani FH, Almosawey HA, Abdullah YJ, Al-Asadi AA, Hameed RM, Hasan NF, Al-Ibraheemi MK. Potential antiviral properties of antifungal drugs. Journal of the Egyptian Women’s Dermatologic Society. 2020 ;17:185.
13- Al-Khikani FH. Amphotericin B as antiviral drug: Possible efficacy against COVID-19. Annals of Thoracic Medicine. 2020;15:118.
14- Guo Y, Cao W, Zhu Y. Immunoregulatory functions of the IL-12 family of cytokines in antiviral systems. Viruses. 2019;11:772.
15- Himani G, Badini A, Nanji K. Depression and its associated factors among patients with chronic obstructive pulmonary disease in Karachi, Pakistan. Cureus. 2018;10:98
16- Jiang S, Shan F, Zhang Y, Jiang L, Cheng Z. Increased serum IL-17 and decreased serum IL-10 and IL-35 levels correlate with the progression of COPD. International journal of chronic obstructive pulmonary disease. 2018;13:2483.
17- Chen Y, Wang CJ, Lin SH, Zhang M, Li SY, Xu F. Interleukin-35 is upregulated in response to influenza virus infection and secondary bacterial pneumonia. Cytokine. 2016;81:23-7.
18- Mabrey FL, Morrell ED, Bhatraju PK, Sathe NA, Sakr SS, Sahi SK, West TE, Mikacenic C, Wurfel MM. Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019. Critical care explorations. 2021;3:67
19- Assal HH, Abdelrahman SM, Abdelbasset MA, Abdelaziz M, Sabry IM, Shaban MM. Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia. International Journal of Infectious Diseases. 2022;118:155-63.
20- Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care 2019;7:22.
21- Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost 2020;46:379–82.
22- Galliera E, Massaccesi L, De Vecchi E, Banfi G, Romanelli MM. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58:11-7.
23- Nagata T, Yasuda Y, Ando M, Abe T, Katsuno T, Kato S, et al. Clinical impact of kidney function on presepsin levels. PLoS One 2015;10:e0129159.